Abiopharma

🔍 Favre Christophe (Executive)

Company: FORRESTER RESEARCH, INC. (FORR)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 3,177 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 15,270.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,532 shares of Common Stock at $5.39 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: false | shares_owned_after: 13,738.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 987 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 1,972.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 2,190 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 6,570.00 | transaction_form_type: 4 | Footnotes: F3, F5, F5

Footnotes:

• F1: Represents the conversion, upon vesting, of restricted stock units into common stock.
• F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on April 1, 2026 of the restricted stock units awarded to the reporting person on April 1, 2024 and April 1, 2025. The awards include a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the awards.
• F3: Each Restricted Stock Unit represents the right to receive, following vesting, one share of Forrester Research, Inc. common stock.
• F4: On April 1, 2024, the reporting person was granted 3,946 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.
• F5: On April 1, 2025, the reporting person was granted 8,760 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.